AOD-9604 is a growth-hormone-derived fragment peptide sold widely today as a fat-loss and joint-repair compound, built on a genuinely clever piece of 1990s endocrinology — a lipolytic domain isolated from the rest of the GH molecule. It also failed its own Phase 2b obesity trial in 2007. Both facts matter, and only one of them shows up in the marketing.
Aod-9604
-
AOD-9604 and the GH Fragment Marketing Gap